BRCA2 and prostate cancer: The National Comprehensive Cancer Network (NCCN, version 2.2021, https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf, accessed on 1 March 2021) Prostate Cancer Early Detection and Prostate Cancer guidelines recommend genetic testing to patients with a history of high- or very high-risk regional or metastatic prostate cancer, or localized disease with intraductal histology, a family history of high-risk germline mutations (e.g., BRCA1 and BRCA2, Ashkenazi Jewish ancestry), or a strong family history of cancer [47].